{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"16"},{"groupId":"OG015","value":"11"},{"groupId":"OG016","value":"25"}],"units":"Participants"}],"description":"The proportion of efficacy-evaluable patients who achieve complete response (CR) or partial response (PR), per investigator assessment, in accordance with RECIST 1.1 or iRECIST (for solid tumor patients) or Response Assessment in Neuro-Oncology (RANO) criteria (for glioblastoma patients).","groups":[{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG000","title":"Dose Regimen A (DR-A) Escalation (0.16 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG001","title":"Dose Regimen A (DR-A) Escalation (0.32 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG002","title":"Dose Regimen A (DR-A) Escalation (0.64 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG003","title":"Dose Regimen A (DR-A) Escalation (1.25 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG004","title":"Dose Regimen A (DR-A) Escalation (2.10 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG005","title":"Dose Regimen A (DR-A) Escalation (3.10 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG006","title":"Dose Regimen A (DR-A) Escalation (4.40 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG007","title":"Dose Regimen B (DR-B) Escalation (0.32 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG008","title":"Dose Regimen B (DR-B) Escalation (0.53 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG009","title":"Dose Regimen B (DR-B) Escalation (0.80 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG010","title":"Dose Regimen B (DR-B) Escalation (1.10 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG011","title":"Dose Regimen B (DR-B) Escalation (1.50 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG012","title":"Dose Regimen B (DR-B) Escalation (2.00 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG013","title":"Dose Regimen B (DR-B) Escalation (2.70 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG014","title":"Dose Regimen A (DR-A) PTCL Expansion"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG015","title":"Dose Regimen C (DR-C) PTCL Expansion"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle Drug: Palbociclib Fixed-dose capsule administered orally on days 1 through 21 of a 28-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG016","title":"Combination With Palbociclib Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The efficacy evaluable population was defined as those patients who met all of the following criteria: (1) Received at least 1 dose of ALRN-6924 at a dose level at least 0.8 mg/kg per infusion (2) Had at least 1 postbaseline evaluation or had clinical disease progression (3) Were TP53 wild type or indeterminate (as assessed by the central laboratory; if not assessed by central laboratory, as assessed by the local laboratory.","reportingStatus":"POSTED","timeFrame":"From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle in DR-A is 28 days, DR-B and DR-C is 21 days), an average of 138 Days","title":"Assess Additional Measures of Anti-tumor Activity, Including Duration of Response, Progression Free Survival, Overall Survival and Time to Response","type":"SECONDARY","unitOfMeasure":"Participants"}